Finding new medicines in nature using artificial intelligence

Enveda has just secured $311 million in new funding to push these nature-inspired drug candidates through human clinical trials. This is a significant step because, while many companies are using technology to speed up research, very few have actually reached the point of testing their results in human patients. The company is currently focusing on drugs for chronic skin conditions and treatments to help people maintain weight loss after they stop using common weight-loss medications.

Normally, drug discovery is like trying to find a specific grain of sand on a massive beach. Scientists identify a biological problem in the body and then spend years testing millions of chemical combinations to see if any of them interact with that problem in a helpful way. Enveda uses artificial intelligence to act as an incredibly fast librarian. Instead of guessing, they train their software to read the chemical signatures of thousands of natural substances. By analyzing the shapes and patterns of these molecules, the AI predicts which ones might be effective at treating specific human diseases. This allows researchers to bypass the early, slow work of trial and error and go straight to testing the most promising natural candidates in the lab.

The success of this approach could change how we find cures for difficult diseases. If the software can accurately predict which natural ingredients will work, we might stop relying solely on synthetic chemistry and start tapping into the vast, untapped library of biology that already exists. While there is still a long path between a computer prediction and a medicine on a pharmacy shelf, moving these projects into human trials is the true test of whether the technology works. If these trials succeed, it would prove that AI can do more than just write text or generate images—it could help us uncover the next generation of medicine.